Announcement • Apr 24
Holista Colltech Limited, Annual General Meeting, May 25, 2026 Holista Colltech Limited, Annual General Meeting, May 25, 2026. Location: stantons international, 40 kings park road, west perth wa 6005, Australia Board Change • Apr 22
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Kwok Lai is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 03
Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0 in FY 2024) Full year 2025 results: AU$0.003 loss per share (further deteriorated from AU$0 in FY 2024). Revenue: AU$5.79m (up 3.1% from FY 2024). Net loss: AU$948.9k (loss widened AU$848.9k from FY 2024). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 02
Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0 in FY 2024) Full year 2025 results: AU$0.003 loss per share (further deteriorated from AU$0 in FY 2024). Revenue: AU$5.79m (up 3.4% from FY 2024). Net loss: AU$948.9k (loss widened AU$848.9k from FY 2024). Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 52% per year. Announcement • Nov 12
Holista Colltech Limited has completed a Follow-on Equity Offering in the amount of AUD 2.295 million. Holista Colltech Limited has completed a Follow-on Equity Offering in the amount of AUD 2.295 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 32,785,714
Price\Range: AUD 0.07
Discount Per Security: AUD 0
Transaction Features: Subsequent Direct Listing Announcement • Oct 30
Holista Colltech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.295 million. Holista Colltech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.295 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 32,785,714
Price\Range: AUD 0.07
Discount Per Security: AUD 0
Transaction Features: Subsequent Direct Listing Reported Earnings • Sep 03
First half 2025 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in 1H 2024) First half 2025 results: AU$0.001 loss per share (improved from AU$0.004 loss in 1H 2024). Revenue: AU$2.89m (up 8.6% from 1H 2024). Net loss: AU$294.6k (loss narrowed 70% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jun 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.0m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-AU$3.4m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (AU$5.6m revenue, or US$3.7m). Market cap is less than US$100m (AU$20.8m market cap, or US$13.6m). Board Change • May 17
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of the Scientific Advisory Board Arthur Martin is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Greg Pilant was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Apr 30
Holista Colltech Limited, Annual General Meeting, May 29, 2025 Holista Colltech Limited, Annual General Meeting, May 29, 2025. Location: stantons international, 40 kings park road, west perth wa 6005 Australia Reported Earnings • Apr 06
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.017 loss in FY 2023) Full year 2024 results: EPS: AU$0 (improved from AU$0.017 loss in FY 2023). Revenue: AU$5.60m (down 5.9% from FY 2023). Net loss: AU$100.1k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 01
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.017 loss in FY 2023) Full year 2024 results: EPS: AU$0 (improved from AU$0.017 loss in FY 2023). Revenue: AU$5.66m (down 4.8% from FY 2023). Net loss: AU$84.2k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Feb 28
Holista Colltech Limited Welcomes Greg Pilant to the Board Holista Colltech Limited welcomed Mr. Greg Pilant to the board with his depth of experience and breath of expertise. These actions underscore a robust commitment to Holista's long-term success and stability in the healthcare space. Mr. Pilant is the founder, CEO, and Chairman of Regenerex Pharma Inc.,which is listed on the OTCB in the United States as well as several other private companies. A lifelong entrepreneur, he established Greystone Pharmaceuticals Inc., and has led various medical and pharmaceutical firms since 1985, including Stanley Pharmaceuticals, National Labs, and MedStat. Announcement • Jan 03
Holista Colltech Limited Appoints Leong Man Loong as Director, Effective January 3, 2025 Holista Colltech Limited announced the appointment of Leong Man Loong as director, effective January 3, 2025. New Risk • Jan 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$590k free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$4.4m). Earnings have declined by 8.5% per year over the past 5 years. Market cap is less than US$10m (AU$4.57m market cap, or US$2.84m). Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Revenue is less than US$5m (AU$5.5m revenue, or US$3.4m). Announcement • May 03
Holista Colltech Limited, Annual General Meeting, May 31, 2024 Holista Colltech Limited, Annual General Meeting, May 31, 2024, at 11:00 W. Australia Standard Time. Location: Stantons International, 40 Kings Park Road West Perth Western Australia Australia Agenda: To consider adoption of remuneration report; to consider election of director-Mr Lai Kwok Kin; to consider -Mr David Deloub; and to consider other matters. Reported Earnings • Mar 01
Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.005 loss in FY 2022) Full year 2023 results: AU$0.008 loss per share (further deteriorated from AU$0.005 loss in FY 2022). Revenue: AU$5.98m (down 27% from FY 2022). Net loss: AU$2.26m (loss widened 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Board Change • Jan 02
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Loren King King was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 05
First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.002 loss in 1H 2022) First half 2023 results: AU$0.004 loss per share (further deteriorated from AU$0.002 loss in 1H 2022). Revenue: AU$3.15m (down 30% from 1H 2022). Net loss: AU$1.15m (loss widened 102% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. New Risk • Sep 01
New major risk - Revenue and earnings growth Earnings have declined by 0.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$695k free cash flow). Earnings have declined by 0.1% per year over the past 5 years. Market cap is less than US$10m (AU$2.79m market cap, or US$1.81m). Minor Risk Revenue is less than US$5m (AU$6.9m revenue, or US$4.4m). Reported Earnings • Mar 04
Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.005 loss in FY 2021) Full year 2022 results: AU$0.005 loss per share (in line with FY 2021). Revenue: AU$8.31m (up 2.6% from FY 2021). Net loss: AU$1.45m (loss widened 16% from FY 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
First half 2022 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2021) First half 2022 results: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2021). Revenue: AU$4.53m (up 27% from 1H 2021). Net loss: AU$567.7k (loss narrowed 9.7% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). CEO, MD & Executive Chairman Rajen Manickavasagar is the most experienced director on the board, commencing their role in 2009. Independent Non-Executive Director Walter Joseph was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Apr 02
Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.02 loss in FY 2020) Full year 2021 results: AU$0.005 loss per share (up from AU$0.02 loss in FY 2020). Revenue: AU$8.10m (up 10% from FY 2020). Net loss: AU$1.26m (loss narrowed 77% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: AU$0.005 loss per share (up from AU$0.02 loss in FY 2020). Revenue: AU$8.12m (up 11% from FY 2020). Net loss: AU$1.26m (loss narrowed 77% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Announcement • Sep 08
Gara Group Files Lawsuit Against Holista Colltech, Ltd On September 3, 2021, Gara Group Inc. filed an amended complaint in the Superior Court of California for the County of San Diego against HOLISTA COLLTECH, LTD (37-2019-00053997-CU-BC-CTL). The lawsuit alleges the Defendant, Holista Colltech Ltd, along with their partner iGalen International Inc., and Dr. Rajen Manicka have breached their contract with Gara Group by refusing to fulfill their obligation to make timely payments, refusing to communicate assurance that payments would be made in a timely manner, and by refusing to operate in good faith to resolve any differences between plaintiff and defendants. The lawsuit alleges that defendant Holista Colltech deliberately failed to make payments, failed to make arrangements for payments with Gara Group, failed to acknowledge the existence of ongoing obligations, and repudiation of its agreed upon obligations under the terms of its contract with Gara Group. The total past due balance allegedly owing is in excess of $408,000.00. Payments were beyond 90 days past due at the time of the initial lawsuit in 2019. Moreover, pursuant to the contract signed by all parties, Gara Group is seeking additional $50,000,000 in liquidated damages Additionally, the lawsuit alleges causes of action against the defendants for Breach of Covenant of Good Faith and Fair Dealing, Quantum Meruit for Work & Labor Furnished, Intentional Misrepresentation, Negligent Misrepresentation, Open Book Account, Intentional Interference with Prospective Economic Advantage, Alter Ego Liability and Accounting. Executive Departure • Aug 04
Independent Non-Executive Chairman Daniel O’Connor has left the company On the 31st of July, Daniel O’Connor's tenure as Independent Non-Executive Chairman ended after less than a year in the role. We don't have any record of a personal shareholding under Daniel's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.50 years. Executive Departure • Jul 06
Non-Executive Director & Company Secretary Blair Michelson has left the company On the 28th of June, Blair Michelson's tenure as Non-Executive Director & Company Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Blair's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.42 years. Executive Departure • Jul 06
Independent Non-Executive Director Heng Fai Chan has left the company On the 28th of June, Heng Fai Chan's tenure as Independent Non-Executive Director ended after 8.0 years in the role. We don't have any record of a personal shareholding under Heng Fai's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.42 years. Announcement • Jun 24
Holista Colltech Limited Reaches an Amicable Out-Of-Court Settlement with Eight Mercatus USA Holista Colltech Limited announced that it has reached an amicable out-of-court settlement with Eight Mercatus USA in respect of the Legal Dispute. The settlement is without admission of any liability of any party, and no compensation is to be paid by either party. Holista and Eight Mercatus USA have also mutually agreed to immediately terminate the partnership agreement mentioned in the Company's ASX announcement dated 14 September 2020 without any claims against each other. Announcement • Jun 18
Holista CollTech Limited Grants Permission Under Special Access Under the Medical Device Holista CollTech Limited announced that it has been granted permission under Special access under the Medical Device (Exemption) Order 2016, from the Medical Devices Authority ("MDA") of Malaysia's Ministry of Health ("MOH") to import and distribute for an antigen rapid test kit (RTK-AG) developed and manufactured by Guangdong Hecin Scientific Inc. ("Hecin") of China. With this approval, the Company has secured an initial order for 15,000 units worth $95,000.00 in Malaysia. The test kits will be used to detect the presence of the SARS-CoV-2 viral antigen from nasal swabs within 15 minutes. It is for screening purposes by healthcare professionals and not the sole basis for diagnosis and exclusion decisions. The maiden order was secured by the Company's wholly owned subsidiary Holista Biotech Sdn. Bhd. from Klinik Mutiara, which is part of Amegajaya Sdn Bhd, a medical consultancy that works closely with MOH and related agencies in Malaysia. With the MDA permission, Holista is only permitted to sell and supply the test kits to the registered healthcare professional at Klinik Mutiara. MDA has stipulated that Holista can import up to 45,000 units of the antigen rapid test kits to Malaysia within the first three months of the permission for importation of medical devices for special access under the Medical Device (Exemption) Order dated 14 June 2021. The first 15,000 units will be shipped by end of June 2021. The order marks the first commercial transaction of SARS-CoV-2 test kits by the Company. Based in Guangzhou, Hecin has developed diagnostic products for nucleic acid, immunofluorescence, flow cytometry, as well as medical reagents, amongst others. Hecin has conducted clinical trials for the antigen test kits. The clinical trial was carried out in Daye City Center for Disease Control and Prevention within China. The clinical performance of Hecin RTK-Antigen test kit against Polymerase Chain Reaction (PCR) Comparator method using nasopharyngeal swabs specimens hasobtained a sensitivity of 96.23% and specificity 99.07% Note 1. Announcement • Apr 25
Holista Colltech Limited Updates on Legal Dispute Holista Colltech Limited ("the company") has been served a writ of summons and a statement of claim by Eight Mercatus (USA) Pte Ltd. ("Eight Mercatus USA") in respect of a defamation claim against the Company in the High Court of Singapore. Holista believes Eight Mercatus USA's claim is without merit and will strongly defend itself against the court action. The claim relates to the wording in an ASX announcement released by Holista on 26 February 2021, which informed shareholders that the company has suspended payments to Eight Mercatus USA for the reasons set out in the ASX Announcement. No dollar value has been attributed to the claim. The company has appointed Ascendant Legal LLC (which is in a Formal Law Alliance with Norton Rose Fulbright (Asia) LLP) to be its legal representative in this lawsuit. The company has 21 days to revert to the writ of summons and the statement of claim. Reported Earnings • Feb 28
Full year 2020 earnings released: AU$0.02 loss per share (vs AU$0.003 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: AU$7.48m (up 1.1% from FY 2019). Net loss: AU$5.44m (loss widened AU$4.75m from FY 2019). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Oct 17
Holista Terminates Term Sheet with Skin Elements Holista Colltech Limited provided the following update on its binding terms sheet signed with Skin Elements Limited that was announced to the market on 2 April 2020. Holista has issued a letter of termination on 15 October 2020 following breaches by Skin Elements of several key conditions of the binding term sheet. Skin Elements has only fulfilled its weekly order and payment obligations until the end of May 2020. Sales by Holista to Skin Elements to date total AUD 111,159, or 18% of the agreed annualised purchase commitment of AUD 600,000. Skin Elements has defaulted since the month of June. 